Table 3.
Risks of all-cause mortality, cardiovascular mortality, and liver-related mortality during follow up according to FLI changes
| Events | Model 1 | Model 2 | Model 3 | Model 4 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | ||
| All-cause mortality | |||||||||||||
| Non-NAFLD | 3,915 | Ref. | Ref. | Ref. | Ref. | ||||||||
| Regressed NAFLD | 257 | 1.477 | 1.302–1.676 | < 0.001 | 1.490 | 1.309–1.696 | < 0.001 | 1.415 | 1.242–1.611 | < 0.001 | 1.320 | 1.158–1.504 | < 0.001 |
| Incident NAFLD | 225 | 1.246 | 1.089–1.425 | 0.001 | 1.550 | 1.349–1.781 | < 0.001 | 1.453 | 1.264–1.671 | < 0.001 | 1.378 | 1.198–1.585 | < 0.001 |
| Persistent NAFLD | 359 | 1.300 | 1.167–1.448 | < 0.001 | 1.886 | 1.674–2.125 | < 0.001 | 1.710 | 1.516–1.929 | < 0.001 | 1.569 | 1.390–1.771 | < 0.001 |
| Persistent NAFLD | 359 | Ref. | Ref. | Ref. | Ref. | ||||||||
| Regressed NAFLD | 257 | 1.137 | 0.968–1.334 | 0.112 | 0.825 | 0.695–0.979 | 0.003 | 0.862 | 0.725–1.024 | 0.091 | 0.879 | 0.739–1.045 | 0.145 |
| CV mortality | |||||||||||||
| Non-NAFLD | 549 | Ref. | Ref. | Ref. | Ref. | ||||||||
| Regressed NAFLD | 33 | 1.353 | 0.952–1.922 | 0.092 | 1.319 | 0.921–1.891 | 0.131 | 1.255 | 0.875–1.799 | 0.217 | 1.115 | 0.777–1.600 | 0.555 |
| Incident NAFLD | 41 | 1.619 | 1.179–2.223 | 0.003 | 1.958 | 1.406–2.726 | < 0.001 | 1.848 | 1.325–2.578 | < 0.001 | 1.673 | 1.199–2.333 | 0.003 |
| Persistent NAFLD | 50 | 1.291 | 0.966–1.724 | 0.084 | 1.807 | 1.313–2.487 | < 0.001 | 1.628 | 1.180–2.246 | 0.003 | 1.421 | 1.028–1.963 | 0.033 |
| Persistent NAFLD | 50 | Ref. | Ref | Ref. | Ref. | ||||||||
| Regressed NAFLD | 33 | 1.045 | 0.673–1.622 | 0.845 | 0.837 | 0.521–1.345 | 0.462 | 0.846 | 0.525–1.362 | 0.492 | 0.859 | 0.533–1.386 | 0.534 |
| Liver-related mortality | |||||||||||||
| Non-NAFLD | 151 | Ref. | Ref. | Ref. | Ref. | ||||||||
| Regressed NAFLD | 14 | 2.086 | 1.207–3.608 | 0.009 | 2.279 | 1.295–4.010 | 0.004 | 1.255 | 0.875–1.799 | 0.217 | 1.986 | 1.123–3.511 | 0.018 |
| Incident NAFLD | 20 | 2.868 | 1.799–4.573 | < 0.001 | 3.855 | 2.346–6.335 | < 0.001 | 1.848 | 1.325–2.578 | < 0.001 | 3.359 | 2.033–5.550 | < 0.001 |
| Persistent NAFLD | 32 | 2.995 | 2.046–4.386 | < 0.001 | 4.833 | 3.085–7.571 | < 0.001 | 1.628 | 1.180–2.246 | 0.003 | 3.887 | 2.446–6.176 | < 0.001 |
| Persistent NAFLD | 32 | Ref. | Ref. | Ref. | Ref. | ||||||||
| Regressed NAFLD | 14 | 0.698 | 0.373–1.308 | 0.262 | 0.421 | 0.218–0.814 | 0.010 | 0.437 | 0.225–0.850 | 0.015 | 0.434 | 0.223–0.846 | 0.014 |
CI confidence interval, CV cardiovascular, HR hazard ratio
Model 1: Crude
Model 2: Age, sex, and body weight
Model 3: Model 2 + alcohol consumption, smoking, regular exercise, and income status
Model 4: Model 3 + hypertension, diabetes mellitus, dyslipidemia, and estimated glomerular filtration rate